|
Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - IMPAQ International |
Research Funding - Akcea Therapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - GE Healthcare |
Other Relationship - Journal of the American College of Radiology. (Inst) |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; Puma Biotechnology; Seagen |
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Merck; Nektar |
Research Funding - Medivation (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst) |
|
|
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate |
Travel, Accommodations, Expenses - Novartis |
|
|
Research Funding - Celgene (Inst); Cephalon (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hospira (Inst); Pharmacyclics (Inst); Polyphenon E International (Inst) |
Patents, Royalties, Other Intellectual Property - Dr. Shanafelt is co-inventor of the Physician Well-being Index and Medical Student Well-being Index. Mayo Clinic holds the copyrights on these instruments. No royalties have been received. (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; ION Pharma; Janssen; Oncopeptides; Roche |
Research Funding - Amgen; Celgene; Janssen |
|
|
Consulting or Advisory Role - Array BioPharma; BioNTech; Bristol-Myers Squibb; Genentech/Roche; HUYA Bioscience International; Immunocore; Incyte; Merck; Newlink Genetics; Novartis; OncoSec; Pfizer/EMD Serono; Sanofi/Regeneron |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Metastat |
Consulting or Advisory Role - Adgero Biopharmaceuticals; AstraZeneca; Cardinal Health; Celgene; Celldex; Genentech/Roche; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Prescient Therapeutics |
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Prescient Therapeutics (Inst); Radius Health (Inst) |
Travel, Accommodations, Expenses - Adgero Biopharmaceuticals; AstraZeneca; Menarini Silicon Biosystems; Myriad Genetics; Pfizer; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda |
|
|
Consulting or Advisory Role - Celgene |
Travel, Accommodations, Expenses - Celgene |